In EARLY TAVR, intervention improved outcomes over waiting in patients with class II or no indications for AVR consideration.

TCTMD ® is produced by the Cardiovascular Research Foundation ® (CRF). CRF ® is committed to igniting the next wave of innovation in research and education that will help doctors save and improve the ...